Clinical trials
Hepatocellular Carcinoma Resectable clinical trials
Below are recruiting hepatocellular carcinoma resectable clinical trials, each written for real people, not researchers. We’re tracking 205 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07062380Recruiting
AI tool to predict liver cancer return after surgery
This study uses an AI tool to predict how liver cancer might come back after surgery. It is for people with early-stage liver cancer who are already scheduled for surgery and have recent MRI scans.
Wuhan, HubeiAges 18–75 - NCT07475026RecruitingPhase 3
Combination therapy before surgery for high-risk liver cancer
This trial tests whether a combination of two drugs (tislelizumab and lenvatinib) given before surgery can lower the risk of liver cancer coming back in people with early-stage but high-risk disease.
TianjinAges 18–75 - NCT06777017Recruiting
Can liver stiffness predict cancer return after ablation?
This trial studies if measuring liver and spleen stiffness can help predict the risk of liver cancer coming back after radiofrequency ablation (RFA), a treatment that uses heat to destroy tumors. It aims to improve follow-up care for people with chronic liver disease and early-stage liver cancer.
BolognaAges 18 years+ - NCT06718153Recruiting
Using protein tests to diagnose liver cancer types
This trial uses special stains on tumor tissue to find genetic changes in liver cancer cells. It may help doctors better diagnose and classify the type of liver cancer you have.
BolognaAges 18 years+ - NCT07290764Enrolling by invitation
Surgery vs observation for liver cancer that responded to drug therapy
This trial looks at whether people with an initially untreatable liver cancer that has shrunk or disappeared after drug therapy should have surgery or just continue monitoring. It aims to see which approach helps people live longer.
Fuzhou, FujianAges 18–75 - NCT07062055RecruitingPhase 2
Combination therapy for advanced liver cancer that has spread
This trial tests a combination of liver-directed treatments and immunotherapy with a targeted drug for people whose liver cancer has spread to a few other organs. It aims to shrink tumors and improve outcomes.
Jinan, ShandongAges 18–70 - NCT04777942Recruiting
New liver cancer treatment plan for high-risk early-stage patients
This trial studies a treatment approach (a combination given through the liver) for people with early liver cancer that can be surgically removed but has a high chance of coming back. It may help reduce the risk of recurrence after treatment.
Guangzhou, GuangdongAges 18–75 - NCT05466565Recruiting
Peginterferon antiviral treatment after liver cancer surgery
This trial studies an antiviral medicine given after surgery for liver cancer to help prevent the cancer from coming back. It focuses on people who are hepatitis B–positive (HBsAg positive) and have complete remission on follow-up checks.
Changsha, HunanAges 18–65 - NCT05534906Recruiting
Detecting very early liver cancer and tracking its natural course
This study looks at how well doctors can detect small, early liver cancer and then follow how it changes over time. It may help your care team choose the best next steps based on earlier, clearer detection.
Oxford, OxfordshireAges 18–100 - NCT05718492Recruiting
Tested HAIC for liver cancer after prior immunotherapy
This trial studies HAIC, a type of targeted treatment delivered into the liver, for advanced hepatocellular carcinoma (liver cancer) that has already been treated with immune and anti-blood-vessel therapies. It aims to see whether HAIC can help control the cancer safely after those earlier treatments.
Guangzhou, GuangdongAges 18–75 - NCT06190665Recruiting
Bead type comparison for liver cancer TACE
This trial compares two types of tiny beads used in a liver cancer treatment called TACE to see which works better. If you have liver cancer that needs TACE and your liver is still working fairly well, you may be able to join.
Beijing, Beijing MunicipalityAges 18–80 - NCT05062837RecruitingPhase 2/Phase 3
Surgery plus two drugs for advanced liver cancer
This trial combines surgery to remove liver tumors with two drugs, camrelizumab (an immunotherapy that helps your immune system fight cancer) and apatinib (a targeted therapy that may cut off the tumor's blood supply). It aims to see if this combination helps people with advanced liver cancer that has spread outside the liver (but not to the brain) and who have chosen not to have other standard treatments like TACE or radiation. Participating could potentially control the spreading cancer and improve outcomes.
NanningAges 18–75 - NCT06215651RecruitingPhase 2
Testing cadonilimab and lenvatinib before liver cancer surgery
This study tests whether a combination of two drugs (cadonilimab and lenvatinib) can shrink liver cancer enough to make it removable by surgery for people whose cancer was previously too advanced for surgery. You may qualify if your cancer hasn't spread far, you haven't had treatment before, and your liver is still working fairly well.
Beijing, Beijing MunicipalityAges 18–75 - NCT03949231RecruitingPhase 3
Infusion immunotherapy through the liver artery for liver cancer
This trial tests a combination of immune “brakes” medicines (PD-1/PD-L1/CTLA-4) delivered through the liver’s artery, to help treat advanced liver cancer. It may help the immune system attack the cancer more effectively, especially if other local liver treatments aren’t possible or have stopped working.
Guanzhou, GuangdongAges 18–80 - NCT07811687Recruiting
Liver and spleen surgery for liver cancer with cirrhosis
This study tests whether removing part of the liver along with the spleen during laparoscopic (keyhole) surgery helps improve liver function and the immune system in people with liver cancer and cirrhosis. If you qualify, you may have better surgical outcomes and recovery.
Yangzhou, JiangsuAges 18–80 - NCT07806292RecruitingPhase 2
Combination therapy for inoperable liver cancer
This study tests a combination of two drugs (anlotinib and benmelstobart) with a liver-directed chemotherapy procedure (HAIC) in people with liver cancer that cannot be removed surgically. The goal is to see if this combo shrinks tumors and is safe.
Guangzhou, GuangdongAges 18–75 - NCT07727759Recruiting
CT scan to predict liver failure after surgery
This trial uses special CT scans to create a map of your liver's blood vessels before surgery. The goal is to predict if your liver might fail after part of it is removed, so doctors can better plan your care.
Minya, Minya GovernorateAges 18 years+ - NCT07628751Recruiting
Standard care versus radiation therapy for early-stage liver cancer
This study compares two treatment approaches for early-stage liver cancer: standard treatments (like ablation or chemotherapy injected into blood vessels) versus a newer radiation therapy called SABR. The goal is to see which approach works better and is safer for patients with a single small tumor.
WaratahAges 18 years+ - NCT07623265Recruiting
Understanding Immunotherapy Response in Liver Cancer
This study collects tumor samples and medical information from patients with liver cancer to understand why some patients respond better to immunotherapy (immune-boosting drugs) than others. The goal is to improve treatment selection and outcomes for future patients.
AntwerpAges 18 years+ - NCT05475613RecruitingPhase 2
Immunotherapy to shrink advanced liver cancer before transplant
This trial tests an immunotherapy “downstaging” plan to shrink hepatocellular carcinoma (a type of liver cancer) so it may become treatable with a liver transplant. You may be eligible if your cancer is beyond transplant limits but is still only in the liver, and you meet specific liver function and health requirements.
Guangzhou, GuangdongAges 18–75 - NCT07594964RecruitingPhase 1
Safety Study of XH001 Injection for High-Risk Recurrent Solid Tumors
This early-stage trial tests a new injection called XH001 as an additional treatment after surgery for patients with high-risk cancers that have come back. The goal is to check if it's safe and whether it helps prevent the cancer from returning again.
BeijingAges 18–70 - NCT07586046RecruitingPhase 2
Radiation treatment for liver tumors
This study tests a higher dose of radiation delivered directly to liver tumors through small beads. It aims to improve tumor control while keeping side effects manageable for people whose liver cancer is not removable by surgery.
Chicago, IllinoisAges 18 years+ - NCT06725121RecruitingPhase 1/Phase 2
Radiation and immunotherapy for advanced liver cancer before transplant
This trial tests combining radiation therapy with immunotherapy (AtezoBev) before a liver transplant for advanced liver cancer. The goal is to see if this approach can shrink tumors and make transplant possible for more people.
London, OntarioAges 18–70 - NCT06805552Recruiting
Sarcopenia and targeted therapy in liver cancer
This study looks at muscle loss in people with liver cancer who are receiving targeted therapy (TKIs). It aims to understand how muscle health affects treatment outcomes. You may qualify if you have intermediate or advanced liver cancer or earlier stage that hasn't responded to prior treatments.
BolognaAges 18 years+
Hear when a new Hepatocellular Carcinoma Resectable trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for hepatocellular carcinoma resectable?
- Yes. Clin2 currently lists 205 recruiting hepatocellular carcinoma resectable studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a hepatocellular carcinoma resectable trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a hepatocellular carcinoma resectable trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.